FDA approves expanded use of Novartis’ Ilaris to treat three rare periodic fever syndromes
Novartis has secured three new approvals from the US Food and Drug Administration (FDA) for the expanded use of Ilaris (canakinumab) to treat three rare types of Periodic Fever Syndromes.
Click on this link for more information.
